Evolus is preparing for the official launch of Evolysse™, a new line of dermal fillers expected to rival Restylane® and Juvéderm®. With FDA approval pending for Q2 2025, medspa providers can now join Evolus’ early access list. Discover how Evolysse™ stands out with longer-lasting effects and advanced formulation technology.